Skip to main content
Search hero banner

Search results

Showing 241 - 260 of 378 results

Chronic Kidney disease of unknown origin

Chronic kidney disease of unknown origin

In 2017, ANSTO's CEO signed a Memorandum of Understanding with Sri Lanka to work together to investigate the epidemiology of Chronic Kidney Disease of unknown origin (CKDu).

Quantum technologies

Quantum technologies

ANSTOs capabilities are ideally suited for these investigations relating to quantum technologies.

Dr Anton Tadich
Senior Scientist, Soft X-ray Spectroscopy Beamline

Role at ANSTO

Submissions to nuclear inquiries

ANSTO has made two public submissions to parliamentary inquiries with another to be submitted in February 2020 on matters relating to nuclear technologies, their peaceful applications, and the nuclear fuel cycle.

Imaging and medical beamline

Imaging and medical

The Imaging and Medical beamline (IMBL) is a flagship beamline of the Australian Synchrotron built with considerable support from the NHMRC. It is one of only a few of its type, and delivers the world’s widest synchrotron x-ray ‘beam’.

High Performance Macromolecular Crystallography Beamline (MX3)

High Performance Macromolecular Crystallography Beamline (MX3)

The High Performance Macromolecular Crystallography beamline will enable the study of very small (sub-5 micrometre) or weakly diffracting crystals, providing a state-of-the-art high-throughput facility for researchers. MX3 will be able to study the structures of large proteins and protein complexes for virology, drug design and industrial applications via goniometer mounted crystals, in-tray screening, or via serial crystallography methods.

Appointment of new ANSTO CEO

The Chair of ANSTO, The Hon Dr Annabelle Bennett, AC SC, announced today that Mr Shaun Jenkinson has been appointed Chief Executive Officer of ANSTO following a global search for the position.

Dr Kathleen Riches
Quality and Risk Manager

Kathleen manages the quality and document management systems, and oversees procedures for inspection, testing, and calibration of equipment and systems, to support the accelerator operations and beam lines.

Michelle Jones Lennon
General Manager – Nuclear Science & Technology Capital Portfolio

Dr Michelle Jones-Lennon leads the delivery of the Capital Portfolio for the Nuclear Science & Technology group across both Lucas Heights and Clayton campuses of ANSTO.  She is also the Program Director for the BRIGHT Pr

Pagination